Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QazCovid-in Vaccine for COVID-19 Prevention
NCT04691908Phase 3Completed
- Sponsor
- Research Institute for Biological Safety Problems
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of QazCovid-in in coronavirus disease 2019 (COVID-19), sponsored by Research Institute for Biological Safety Problems. Started Dec 2020; status: completed.
02
Drugs
QazCovid-in
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04691908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691908.